Filing Flows › Comparisons › VNRX vs IMDX
Volitionrx vs Insight Molecular Diagnostics: VNRX and IMDX compared
Volitionrx is the larger company: $399K of revenue in its latest quarter (Q2 2026) against $239K for Insight Molecular Diagnostics (Q2 2026). Volitionrx is growing faster (-2% against -54% a year earlier).
Where the money goes: VNRX and IMDX
Volitionrx (VNRX) · Q2 2026
Volitionrx, Q2 2026: revenue $399K (-2% year over year), net loss $7.3M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
Insight Molecular Diagnostics (IMDX) · Q2 2026
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
| Volitionrx (VNRX) | Insight Molecular Diagnostics (IMDX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $399K | $239K |
| Revenue growth, Y/Y | -2% | -54% |
| Operating margin | n/m | n/m |
| Net earnings | −$7.3M | −$11.3M |
| Operating cash flow | −$5.2M | −$9.3M |
Where the revenue comes from
Insight Molecular Diagnostics
- Laboratory Services: $218K (91%)
- Kitted Products: $21K (9%)
Questions
Which is bigger, Volitionrx or Insight Molecular Diagnostics?
Volitionrx is the larger company: $399K of revenue in its latest quarter (Q2 2026) against $239K for Insight Molecular Diagnostics (Q2 2026).
Is Volitionrx or Insight Molecular Diagnostics growing faster?
Volitionrx is growing faster (-2% against -54% a year earlier).
More: Volitionrx earnings · how Volitionrx makes money · Insight Molecular Diagnostics earnings · how Insight Molecular Diagnostics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.